Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep 25;18(1):66.
doi: 10.1186/s13024-023-00656-x.

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023

Sam Gandy  1   2   3
Affiliations
Editorial

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023

Sam Gandy. Mol Neurodegener. .
No abstract available

Keywords: Aducanumab; Bapineuzumab; Donanemab; Lecanemab.

PubMed Disclaimer

Conflict of interest statement

Above.

References

    1. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020;15(1):40. doi: 10.1186/s13024-020-00391-7.PMID:32677986;PMCID:PMC7364557. - DOI - PMC - PubMed
    1. Gandy S, Knopman DS, Sano M. Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Mol Neurodegener. 2021;16(1):74. doi: 10.1186/s13024-021-00490-z.PMID:34736482;PMCID:PMC8569969. - DOI - PMC - PubMed
    1. Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023;32(2):89–94. doi: 10.1080/13543784.2023.2178414.PMID:36749830;PMCID:PMC10275297. - DOI - PMC - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9–21. doi: 10.1056/NEJMoa2212948. - DOI - PubMed
    1. Cynis H, Frost JL, Crehan H, Lemere CA. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener. 2016;11(1):48. doi: 10.1186/s13024-016-0115-2.PMID:27363697;PMCID:PMC4929720. - DOI - PMC - PubMed

Publication types

Substances